Shares of Neos Therapeutics Inc (NASDAQ:NEOS) traded up 6.7% on Wednesday . The stock traded as high as $11.35 and last traded at $11.20. 883,905 shares changed hands during trading, an increase of 130% from the average session volume of 384,991 shares. The stock had previously closed at $10.50.

Several analysts have weighed in on the company. Zacks Investment Research raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 18th. Cowen reaffirmed a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. BidaskClub raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, Wells Fargo & Co set a $14.00 price objective on Neos Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $14.00.

The company has a market cap of $324.77 and a price-to-earnings ratio of -3.22. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.22. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. The firm had revenue of $6.70 million during the quarter. equities analysts predict that Neos Therapeutics Inc will post -2.87 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in NEOS. Schwab Charles Investment Management Inc. lifted its holdings in shares of Neos Therapeutics by 103.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock valued at $320,000 after purchasing an additional 22,200 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Neos Therapeutics by 13.6% during the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after purchasing an additional 2,441 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Neos Therapeutics by 13.0% during the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock valued at $396,000 after purchasing an additional 6,223 shares during the last quarter. Alliancebernstein L.P. purchased a new position in shares of Neos Therapeutics during the second quarter valued at approximately $161,000. Finally, Teachers Advisors LLC lifted its holdings in shares of Neos Therapeutics by 31.0% during the second quarter. Teachers Advisors LLC now owns 38,853 shares of the company’s stock valued at $284,000 after purchasing an additional 9,190 shares during the last quarter. Hedge funds and other institutional investors own 45.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Neos Therapeutics (NEOS) Trading 6.7% Higher” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/neos-therapeutics-neos-trading-6-7-higher/1813923.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.